NCT04397796View on ClinicalTrials.gov

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

September 6, 2020

Study Completion Date

September 6, 2020

Conditions
COVID
Interventions
BIOLOGICAL

BM-Allo.MSC

BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.

BIOLOGICAL

Placebo

plasmalyte and human albumin

Trial Locations (1)

90262

St. Francis Medical Center, Lynwood

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY

NCT04397796 - Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | Biotech Hunter | Biotech Hunter